Covid-19: MedinCell presents positive first results from the clinical trial aiming at validating the safety of continuous administration of Ivermectin
Already 3 programs in Clinical
PRECLINICAL & CLINICAL DEVELOPMENT
As of february, 2020
As of December, 2020
130+ people, all shareholders, driven to impact health
Building a global pharma leader through long-acting injectables working with NGOs, Private Sector, and Academics
We’ve broken every barrier to enabling long-acting injectable adoption
Who we are
Who we are
MedinCell is operated by our talented employees who have come together from around the world to achieve our mission of Better Medicine for All.
Through purposeful innovation, we aim to improve the treatments available to patients. And we believe that everyone should have access to best-in-class medication, so we focus on making our products available regardless of local economic conditions. To ensure access, we work on both for-profit and non-profit projects, in collaboration with highly valued partners ranging from big pharmas to physicians, from biotech firms to academics and foundations. Most importantly, our partners share our values based on trust and transparency.